Open access

652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors
Aung Naing, Hirva Mamdani, Minal Barve, Meredith Pelster, Cara Haymaker, Mohamed Derbala, Jack Goon, Samuel Darko, Julie Murphy, Lauren Gorelik, Allison Bierly, Sara Ferrando-Martinez, Byung Ha Lee, Se Hwan Yang, Siyoung Lee, Marya Chaney, Richard D Kim

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A743; DOI: 10.1136/jitc-2023-SITC2023.0652
653 Neoadjuvant CAN-2409+Prodrug plus chemoradiation for borderline resectable or locally advanced non-metastatic pancreatic adenocarcinoma (PDAC)
W Garrett Nichols, Mark Bloomston, David Huitzil, Vanessa Rosas-Camargo, Elizabeth Webber, Marcos Ramirez-Marquez, Alejandra Murillo-Cordova, Randy Swan, Jessica Dwyer, Francesca Barone, Paul P Tak

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A744; DOI: 10.1136/jitc-2023-SITC2023.0653
654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Daniel J Olson, Ecaterina Dumbrava, Mridula George, Sam Saibil, Marcus Butler, Antonio Giordano, Brooke Pieke, Miriam Gavriliuc, Emily Lichtenstein, Jill Geisberger, Maria Apostolopoulou, Kara Moss, D’Arcy Kirkwood, Salina Dang, Deyaa Adib, Benjamin Schlechter

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A745; DOI: 10.1136/jitc-2023-SITC2023.0654
655 Dissecting pancreatic cancer tumor-immune microenvironment crosstalk using spatial transcriptomics
Amaya Pankaj, Arnav Mehta, Michael J Raabe, Julie L Koenig, Bidish Patel, Evan R Lang, Joshua Kocher, Katherine Xu, Linda Nieman, Alec Kimmelman, David Ryan, William Hwang, Martin Aryee, Theodore Hong, Aparna R Parikh, David Ting

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A746-A747; DOI: 10.1136/jitc-2023-SITC2023.0655
656 ELI-002 immunotherapy induces broad polyfunctional T cell responses in subjects with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer
James R Perry, Lochana M Seenappa, Haley VanWyk, Amy M Tavares, Esther Welkowsky, Christopher M Haqq, Peter C DeMuth, Lisa K McNeil

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A748; DOI: 10.1136/jitc-2023-SITC2023.0656
657 A combination treatment of bone marrow-derived CD141⁺dendritic cells and PD1/PD-L1 inhibitors for effective immunotherapy for solid tumors
Jeong Seong Mun, SungYoon Cho, Youngjoo Jeon, Jisun Lim, Gawhan Lee, Sungeun Yun, Hyunsoo Kim

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A749; DOI: 10.1136/jitc-2023-SITC2023.0657
658 Preoperative short course radiotherapy with envafolimab, endostatin and SOX regimen in locally advanced gastric
Dandan Yu, Peng Zhang, Lei Zhao, Pingdong Li, Zhenyu Lin, Yupin Yin, Jin Wang, Kaixiong Tao, Tao Zhang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A750; DOI: 10.1136/jitc-2023-SITC2023.0658
659 Repeated dosing of anti-Claudin 18.2 CAR-T in metastatic gastrointestinal cancer
Dan Zhao, Amanda Olson, Mariela Blum Murphy, So Jung Hong, Hong Ma, Zonghai Li, Raffaele Baffa

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A751; DOI: 10.1136/jitc-2023-SITC2023.0659
660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)
Omar Alhalabi, Rahul Sheth, Amishi Shah, Tharekeswara Bathala, Sergio P Klimkowsky, Wei Qiao, Jianfeng Chen, Xinmiao Yan, Sangeeta Goswami, Ana Adriazola, Arlene Siefker-Radtke, Matthew Campbell, Linghua Wang, Charles Guo, Jianjun Gao

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A752; DOI: 10.1136/jitc-2023-SITC2023.0660
661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype
Moses K Donkor, Veena Agarwal, Sherry Kupchick, Rashmi Deshpande, Dawn Newmin, Vincent O’Neill

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A753; DOI: 10.1136/jitc-2023-SITC2023.0661

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages